[Management of phosphate in chronic kidney disease--Phosphorus control by hemodialysis with long treatment time].
Hyperphosphatemia is an almost universal finding in patients with end-stage renal disease and is associated with increased all-cause mortality, cardiovascular mortality, and vascular calcification. Although new phosphate binders lead to a easy control of serum phosphorus levels, treatment time of a dialysis session might be the most important factor for controlling hyperphosphatemia. Two alternatives to conventional thrice weekly dialysis (CHD) are nocturnal hemodialysis (NHD) and short daily hemodialysis (SDHD) . The total weekly phosphorus removal with NHD and SDHS is significantly greater than that removed by CHD and this is associated with a significantly lower average serum phosphorous.
Tanaka
Motoko
M
Akebono Clinic.
D002908:Chronic Disease; D006801:Humans; D054559:Hyperphosphatemia / Q000209:etiology / Q000628:therapy; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy*; D010758:Phosphorus / Q000302:isolation & purification; D011379:Prognosis; D006435:Renal Dialysis / Q000379:methods; D013997:Time Factors
D010758:Phosphorus